Inventor · disambiguated record
Jin Q. Cheng
Also filed as: CHENG JIN · CHENG JIN Q
37 granted patents·12 pending applications·62 citations·filing 2005–2017
96Inventor score
Top patents by PatentIndex Score
49 records- 0192US9410956B1Micro-RNA profiling in ovarian cancerCHENG JIN Q·Filed 2009·Granted Aug 9, 2016·20 cites·1 claims
- 0291US8183249B2Inhibitors of AKT/PKB with anti-tumor activityCHENG JIN Q·Filed 2008·Granted May 22, 2012·8 cites·16 claims
- 0389US8435959B2Effective treatment of tumors and cancer with triciribine and related compoundsCHENG JIN Q·Filed 2005·Granted May 7, 2013·12 cites·18 claims
- 0482US8901086B2Compositions including triciribine and methods of use thereofCHENG JIN Q·Filed 2012·Granted Dec 2, 2014·2 cites·18 claims
- 0580US8623834B2Compositions including triciribine and trastuzumab and methods of use thereofCHENG JIN Q·Filed 2012·Granted Jan 7, 2014·2 cites·17 claims
- 0677US9498492B2Compositions including triciribine and taxanes and methods of use thereofUNIV SOUTH FLORIDA·Filed 2015·Granted Nov 22, 2016·1 cites·14 claims
- 0777US9115162B2Effective treatment of tumors and cancer with triciribine and related compoundsUNIV SOUTH FLORIDA·Filed 2013·Granted Aug 25, 2015·2 cites·17 claims
- 0877US8435550B2Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical deviceCHENG JIN·Filed 2008·Granted May 7, 2013·8 cites·13 claims
- 0976US9453049B2Substrate-mimetic Akt inhibitorSEBTI SAID M·Filed 2014·Granted Sep 27, 2016·1 cites·13 claims
- 1076US8828451B2Akt sensitization of cancer cellsSEBTI SAID M·Filed 2007·Granted Sep 9, 2014·2 cites·5 claims
- 1176US8822524B2Substrate-mimetic Akt inhibitorSEBTI SAID M·Filed 2009·Granted Sep 2, 2014·1 cites·5 claims
- 1275US2011008327A1Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereofCHENG JIN Q·Filed 2008·Application pending·0 cites
- 1374US2010009929A1Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereofCHENG JIN Q·Filed 2008·Application pending·0 cites
- 1474US2010009928A1Compositions including triciribine and taxanes and methods of use thereofCHENG JIN Q·Filed 2008·Application pending·0 cites
- 1572US9265783B2Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereofUNIV SOUTH FLORIDA·Filed 2013·Granted Feb 23, 2016·0 cites·13 claims
- 1672US9192645B2Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereofUNIV SOUTH FLORIDA·Filed 2014·Granted Nov 24, 2015·0 cites·15 claims
- 1772US8476241B2Effective treatment of esophogeal adenocarcinoma using triciribine and related compoundsCHENG JIN Q·Filed 2011·Granted Jul 2, 2013·1 cites·20 claims
- 1870US9359347B2Inhibitors of Akt/PKB with anti-tumor activityCHENG JIN Q·Filed 2012·Granted Jun 7, 2016·1 cites·14 claims
- 1970US9211299B2Compositions including triciribine and one or more platinum compounds and methods of use thereofUNIV SOUTH FLORIDA·Filed 2013·Granted Dec 15, 2015·0 cites·20 claims
- 2069US10744148B2Methods of treating breast cancer that overexpress AKT kinaseUNIV SOUTH FLORIDA·Filed 2017·Granted Aug 18, 2020·0 cites·22 claims
- 2169US9511084B2Compositions including triciribine and methods of use thereofUNIV SOUTH FLORIDA·Filed 2014·Granted Dec 6, 2016·1 cites·15 claims
- 2269US9150604B2Effective treatment of esophogeal adenocarcinoma using triciribine and related compoundsUNIV SOUTH FLORIDA·Filed 2013·Granted Oct 6, 2015·0 cites·20 claims
- 2369US8906869B2Effective treatment of ovarian cancer using triciribine and related compoundsUNIV SOUTH FLORIDA·Filed 2013·Granted Dec 9, 2014·0 cites·19 claims
- 2468US10780104B2Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereofUNIV SOUTH FLORIDA·Filed 2017·Granted Sep 22, 2020·0 cites·22 claims
- 2567US8673867B2Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereofCHENG JIN Q·Filed 2012·Granted Mar 18, 2014·0 cites·19 claims
- 2666US10076534B2Effective treatment of ovarian cancer using triciribine and related compoundsUNIV SOUTH FLORIDA·Filed 2016·Granted Sep 18, 2018·0 cites·18 claims
- 2766US9655914B2Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereofUNIV SOUTH FLORIDA·Filed 2015·Granted May 23, 2017·0 cites·19 claims
- 2866US9186403B2Compositions including triciribine and trastuzumab and methods of use thereofUNIV SOUTH FLORIDA·Filed 2013·Granted Nov 17, 2015·0 cites·13 claims
- 2966US2017080007A1Effective treatment of esophageal adenocarcinoma using triciribine and related compoundsUNIV SOUTH FLORIDA·Filed 2016·Application pending·0 cites
- 3066US2009239818A1Effective treatment of ovarian cancer using triciribine and related compoundsCHENG JIN Q·Filed 2008·Application pending·0 cites
- 3166US2010028339A1Compositions including triciribine and trastuzumab and methods of use thereofCHENG JIN Q·Filed 2008·Application pending·0 cites
- 3265US9457040B2Effective treatment of esophageal adenocarcinoma using triciribine and related compoundsUNIV SOUTH FLORIDA·Filed 2015·Granted Oct 4, 2016·0 cites·19 claims
- 3365US9433635B2Effective treatment of ovarian cancer using triciribine and related compoundsUNIV SOUTH FLORIDA·Filed 2014·Granted Sep 6, 2016·0 cites·7 claims
- 3465US8865666B2Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereofCHENG JIN Q·Filed 2012·Granted Oct 21, 2014·0 cites·16 claims
- 3565US8691779B2Compositions including triciribine and taxanes and methods of use thereofCHENG JIN Q·Filed 2012·Granted Apr 8, 2014·0 cites·16 claims
- 3665US8673868B2Compositions including triciribine and one or more platinum compounds and methods of use thereofCHENG JIN Q·Filed 2012·Granted Mar 18, 2014·0 cites·19 claims
- 3764US9486492B2Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereofUNIV SOUTH FLORIDA·Filed 2015·Granted Nov 8, 2016·0 cites·9 claims
- 3864US2010173864A1Compositions including triciribine and one or more platinum compounds and methods of use thereofCHENG JIN Q·Filed 2008·Application pending·0 cites
- 3963US9486470B2Compositions including triciribine and one or more platinum compounds and methods of use thereofUNIV SOUTH FLORIDA·Filed 2015·Granted Nov 8, 2016·0 cites·16 claims
- 4061US9518079B2Effective treatment of tumors and cancer with triciribine and related compoundsUNIV SOUTH FLORIDA·Filed 2015·Granted Dec 13, 2016·0 cites·15 claims
- 4161US9101641B2Compositions including triciribine and taxanes and methods of use thereofUNIV SOUTH FLORIDA·Filed 2013·Granted Aug 11, 2015·0 cites·17 claims
- 4261US8178502B2Effective treatment of esophogeal adenocarcinoma using triciribine and related compoundsCHENG JIN Q·Filed 2008·Granted May 15, 2012·0 cites·21 claims
- 4360US9896668B2Substrate-mimetic AKT inhibitorUNIV SOUTH FLORIDA·Filed 2016·Granted Feb 20, 2018·0 cites·17 claims
- 4458US2011223154A1Compositions including triciribine and methods of use thereofUNIV SOUTH FLORIDA·Filed 2008·Application pending·0 cites
- 4556US9486522B2Compositions including triciribine and trastuzumab and methods of use thereofUNIV SOUTH FLORIDA·Filed 2015·Granted Nov 8, 2016·0 cites·12 claims
- 4651US2008107630A1Human matrix metalloproteinase-8 gene delivery enhances the oncolytic activity of a replicating adenovirusUNIV NEW YORK·Filed 2007·Application pending·0 cites
- 4749US2012134964A1Human matrix metalloproteinase-8 gene delivery enhances the oncolytic activity of a replicating adenovirusHAY JOHN G·Filed 2011·Application pending·0 cites
- 4845US2008020014A1Implantable devices containing nuclear receptor ligands for the treatment of vascular and related disordersCONSIGNY PAUL·Filed 2007·Application pending·0 cites
- 4943US2006030536A1Combination therapies for cancer and proliferative angiopathiesUNIV SOUTH FLORIDA·Filed 2005·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →